JAK2 (Phospho-Tyr1007) Antibody Blocking Peptide (GWB-FA1692)



0.1 mg
Add to Cart


Function: Plays a role in leptin signaling and control of body weight (By similarity). Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.

Catalytic Activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.

Subunit: Interacts with SIRPA and SH2B1 (By similarity). Interacts with IL23R, SKB1 and STAM2.

Subcellular Location: Intracytoplasmic membrane; Peripheral membrane protein (By similarity). Note=Wholly intracellular, possibly membrane associated (By similarity).

Tissue Specificity: Expressed in blood, bone marrow and lymph node.

Domain: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.

Ptm: Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813 (By similarity).

Disease: Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.

Disease: Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.

Disease: Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.

Disease: Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.

Disease: Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.

Disease: Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.

Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.

Similarity: Contains 1 FERM domain.

Similarity: Contains 1 protein kinase domain.

Similarity: Contains 1 SH2 domain.

Additional Information

Name JAK2 (Phospho-Tyr1007) Antibody Blocking Peptide (GWB-FA1692)
Related Product Names EC; Janus kinase 2; JAK-2 JAK2 (Phospho-Tyr1007) Antibody Blocking PeptideJAK2
Swissprot ID O60674
NCBI Acc Number NP_004963.1
Molecular Weight 130674
Datasheets/Manuals Printable datasheet for GWB-FA1692
Intended Use Research Use Only